Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

Retrieved on: 2020-12-15 13:06:46

Tags for this article:

Click the tags to see associated articles and topics

Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer. View article details on hiswai:

Excerpt

... a letter from the US Food and Drug Administration (FDA) removing a partial clinical hold on Nascent's proprietary <b>monoclonal antibody</b> Pritumumab.

Article found on: www.digitaljournal.com

View Original Article